# Ionis Pharmaceuticals (IONS) — Earnings

IONS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ions/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.69 |
| EPS estimate | −$1.08 |
| EPS surprise | +36.17% |
| Revenue surprise | +41.73% |
| Revenue | $268.0M |
| Revenue estimate | $189.1M |
| Reported | Jul 29, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/874015/000087401526000251/form10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/ebc6047b-e8b6-4164-01ba-6e5c2314ad82.html) |

Ionis Pharmaceuticals reported Q2 2026 results on July 29, 2026. The company posted a loss of $0.69 per share, narrower than the $1.08 loss analysts expected, a 36.17% beat. Revenue was $268.0 million, well above the $189.1 million consensus, a 41.73% beat. Q2 2025 had been profitable, at $0.70 per share on $452.0 million of revenue. Against that quarter, revenue fell about 41%.

Ionis lost money in every full year shown: $1.90 per share in 2022, $2.56 in 2023, $3.04 in 2024 and $2.44 in 2025. Only two of the last 20 quarters were profitable, Q4 2021 at $1.41 and Q2 2025 at $0.70. Those two quarters also brought the largest revenue in the table, $440.0 million and $452.0 million. The widest loss was $1.41 in Q4 2025. Results have still tended to beat expectations. Ionis topped the EPS estimate in 16 of the last 20 quarters.

The company reported its Q3 results between October 29 and November 9 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue stays above the $246.0 million to $268.0 million of the first half.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 29, 2026 | −$1.08 | −$0.69 | 36.17% | $189.1M | $268.0M |
| Q1 2026 | Apr 29, 2026 | −$0.88 | −$0.56 | 36.11% | $195.6M | $246.0M |
| Q4 2025 | Feb 25, 2026 | −$1.31 | −$1.41 | -7.35% | $158.2M | $203.0M |
| Q3 2025 | Oct 29, 2025 | −$1.22 | −$0.80 | 34.33% | $130.3M | $157.0M |
| Q2 2025 | Jul 30, 2025 | −$0.09 | $0.70 | 868.39% | $298.3M | $452.0M |
| Q1 2025 | Apr 30, 2025 | −$1.10 | −$0.93 | 15.29% | $131.4M | $132.0M |
| Q4 2024 | Feb 19, 2025 | −$1.12 | −$0.66 | 41.29% | $135.3M | $227.0M |
| Q3 2024 | Nov 6, 2024 | −$1.14 | −$0.95 | 16.48% | $129.6M | $134.0M |
| Q2 2024 | Aug 1, 2024 | −$0.94 | −$0.45 | 51.95% | $156.1M | $225.0M |
| Q1 2024 | May 7, 2024 | −$1.05 | −$0.98 | 6.44% | $131.4M | $119.0M |
| Q4 2023 | Feb 21, 2024 | −$0.80 | −$0.06 | 92.50% | $174.1M | $325.0M |
| Q3 2023 | Nov 2, 2023 | −$1.01 | −$1.03 | -2.15% | $136.9M | $144.0M |
| Q2 2023 | Aug 9, 2023 | −$0.88 | −$0.60 | 32.05% | $140.4M | $188.0M |
| Q1 2023 | May 3, 2023 | −$0.87 | −$0.87 | 0.02% | $128.2M | $131.0M |
| Q4 2022 | Feb 22, 2023 | −$0.94 | −$0.37 | 60.63% | $160.1M | $152.0M |
| Q3 2022 | Nov 9, 2022 | −$0.72 | −$0.33 | 54.38% | $143.9M | $160.0M |
| Q2 2022 | Aug 9, 2022 | −$0.61 | −$0.74 | -21.29% | $140.5M | $134.0M |
| Q1 2022 | May 4, 2022 | −$0.69 | −$0.46 | 33.06% | $122.5M | $142.0M |
| Q4 2021 | Feb 24, 2022 | −$0.04 | $1.41 | 3326.54% | $275.6M | $440.0M |
| Q3 2021 | Nov 3, 2021 | −$0.49 | −$0.58 | -18.97% | $160.1M | $133.0M |

## Frequently Asked Questions

### When did Ionis Pharmaceuticals (IONS) last report earnings?

Ionis Pharmaceuticals last reported on Jul 29, 2026, covering fiscal Q2 2026.

### Did IONS beat earnings estimates?

Yes. Ionis Pharmaceuticals reported EPS of −$0.69 for Q2 2026 against a −$1.08 estimate — a 36.17% beat.

### How much revenue did IONS report last quarter?

Ionis Pharmaceuticals reported $268.0M in revenue for Q2 2026, against a consensus estimate of $189.1M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).